MedTrace Logo

Ketamine for Major Depressive Disorder

NCT03721900 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-04-25

No results posted yet for this study

Summary

The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.

Conditions

Interventions

DRUG

SHX-001 Active low dose

ketamine transdermal patch

DRUG

Placebo

transdermal patch

DRUG

SHX-001 Active High dose

ketamine transdermal patch

Sponsors & Collaborators

  • Shenox Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • Mason Freeman, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-28
Primary Completion
2019-06-06
Completion
2019-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03721900 on ClinicalTrials.gov